Brief: Guerbet Says EMA, FDA Agree To Review Gadopiclenol Marketing Authorisation
March 29 (Reuters) - Guerbet SA GRBT.PA :
* EMA AND FDA AGREE TO EVALUATE THE MARKETING AUTHORISATION
APPLICATION DOSSIERS FOR GADOPICLENOL
* THE FDA HAS ACCEPTED THE REQUEST FOR PRIORITY REVIEW,
WHICH
COMMITS IT TO RULE ON THE FILE BY SEPTEMBER 21, 2022
* FILES ARE SUPPORTED BY DATA FROM TWO PHASE III STUDIES OF
GADOPICLENOL
Source text for Eikon: ID:nGNE9bcV0F
Further company coverage: GRBT.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48587696600;))
Recent news on Guerbet SA
See all newsBrief: Guerbet Q1 Revenue At EUR 177.4 Mln
Guerbet Q1 revenue up 2.6% at CER on increased volumes in EMEA and Asia
Medical imaging firm Guerbet's 2025 revenue falls on lower sales activity in France
Brief: Guerbet Says FDA Approves Labeling Update For Guerbet's Elucirem Injection
France's Guerbet misses 2025 revenue estimates